July 24, 2017 3:50 AM ET


Company Overview of Tobira Therapeutics, Inc.

Company Overview

Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat liver disease, inflammation, fibrosis, and HIV. Its lead product candidate includes cenicriviroc, an immunomodulator and dual inhibitor of CCR2 and CCR5, which is in Phase 2a study for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis disease; and Phase 2b study for HIV. The company was founded in 2006 and is headquartered in South San Francisco, California. As of November 1, 2016, Tobira Therapeutics, Inc. operates as a subsidiary of Allergan plc.

701 Gateway Boulevard

Suite 300

South San Francisco, CA 94080

United States

Founded in 2006

19 Employees



Key Executives for Tobira Therapeutics, Inc.

Chief Executive Officer
Age: 53
Age: 54
Chief Financial Officer and Head of Corporate Development
Age: 38
Chief Operating Officer
Age: 53
Chief Medical Officer
Age: 53
Compensation as of Fiscal Year 2017.

Tobira Therapeutics, Inc. Key Developments

Tobira Therapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 03:45 PM

Tobira Therapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 03:45 PM. Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States. Speakers: Laurent Fischer, Chief Executive Officer.

Tobira Therapeutics Files Form 15

Tobira Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.001 par value under the Securities Exchange Act of 1934, as amended.

Tobira Therapeutics, Inc. Announces Executive Changes

On June 3, 2015, Tobira entered into a sales agreement with Cowen and Company, LLC, pursuant to which Tobira could issue and sell, from time to time through Cowen, shares of Tobira's common stock having an aggregate offering price of up to $40.0 million. Effective October 31, 2016, Tobira terminated the Sales Agreement. Pursuant to the Merger Agreement, as of the Effective Time, Carol L. Brosgart, M.D., Jeffrey H. Cooper, Laurent Fischer, M.D., Andrew J. Fromkin, Patrick Heron, Pierre Legault, Gwen A. Melincoff, Dennis Podlesak and Eckard Weber, M.D., each resigned and ceased to be directors of Tobira and members of any committee of Tobira's Board of Directors. Pursuant to the Merger Agreement, as of the Effective Time, the directors and officers of Purchaser immediately prior to the Effective Time became the directors and officers of the Surviving Corporation. The directors of Purchaser immediately prior to the effective time were Kira Schwartz and Sigurd Kirk. As of the Effective Time, Tobira's Board of Directors appointed A. Robert D. Bailey as President, Stephen Kaufhold as Treasurer and Kira Schwartz as Secretary.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

September 20, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tobira Therapeutics, Inc., please visit www.tobiratherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.